Liposomal Wnt Composition for Osseointegration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current orthopedic and dental implants face high failure rates due to inadequate osseointegration at the implant-bone interface, with existing surface modifications and protein-based approaches showing modest or no significant improvements in osseointegration and bone regeneration.
Innovation Solution
The use of Wnt proteins inserted in the non-aqueous phase of a lipid structure, such as liposomes, to enhance osteogenesis and accelerate osseointegration by stimulating osteoprogenitor cell proliferation and bone apposition around implants, thereby extending the functional lifespan of orthopedic and dental implants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein-based approaches (such as BMPs or VEGF) are used to stimulate osseointegration, then bone formation is promoted, but the results are modest or contraindicated due to inhibition of osteogenic differentiation
Solution Approach 1:
The patent changes the delivery parameter of Wnt proteins from aqueous phase to non-aqueous phase (lipid structure), which fundamentally alters the biological activity. This parameter change enables Wnt proteins to function effectively without the inhibitory effects seen with conventional protein delivery methods, resolving the contradiction between promoting bone formation and avoiding inhibition of osteogenic differentiation
Solution Approach 2:
The patent introduces a lipid structure as an intermediary carrier for Wnt proteins. This intermediary enables the Wnt proteins to reach target cells effectively while maintaining their biological activity, avoiding the inhibitory effects associated with direct protein application. The lipid structure serves as a mediator that facilitates effective Wnt signaling for bone formation
2Ease of operation
If Wnt proteins are delivered in aqueous phase, then they are easily administered, but they are ineffective compared to non-aqueous phase delivery
Solution Approach 1:
The patent changes the physical state parameter of Wnt protein delivery from aqueous to non-aqueous phase using lipid structures. This parameter change transforms the delivery system from ineffective to highly effective, maintaining ease of administration while dramatically improving biological activity and osseointegration outcomes
3Productivity
If persistent Wnt activation is maintained, then bone regeneration is continuous, but detrimental consequences occur due to uncontrolled proliferation
Solution Approach 1:
The patent employs periodic or controlled Wnt protein delivery rather than continuous activation. By using lipid structures that can be administered at specific intervals, the system achieves sufficient bone regeneration while avoiding the detrimental effects of persistent Wnt activation. The controlled timing and dosing prevent uncontrolled proliferation while maintaining effective bone formation
Data Source
AI summary
Methods and compositions are provided for the therapeutic use of Wnt proteins, for enhancing bone growth and regeneration, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time.